Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi IndiaBOM:500674 -0.54%77 PB Ratio is 10.36 as of Jul. 28, 2026, which is 120% above its 10-year median of 4.70. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,404.20 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Sanofi India ranks worse than 92.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-28), Sanofi India's share price is ₹3369.25. Sanofi India's Book Value per Share for the quarter that ended in Mar. 2026 was ₹325.30. Hence, Sanofi India's PB Ratio of today is 10.36.
Good Sign:
Sanofi India Ltd stock PB Ratio (=10.41) is close to 3-year low of 9.57.
The historical rank and industry rank for Sanofi India's PB Ratio or its related term are showing as below:
BOM:500674'
s PB Ratio Range Over the Past 10 Years
Min: 2.68 Med: 4.7 Max: 24.7
Current: 10.35
During the past 13 years, Sanofi India's highest PB Ratio was 24.70. The lowest was 2.68. And the median was 4.70.
BOM:500674's PB Ratio is ranked worse than 92.94% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs BOM:500674: 10.35
During the past 12 months, Sanofi India's average Book Value Per Share Growth Rate was -12.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sanofi India was 18.80% per year. The lowest was -27.10% per year. And the median was 9.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sanofi India PB Ratio Related Terms
Sanofi India PB Ratio Historical Data
* Premium members only.
The historical data trend for Sanofi India's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi India's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sanofi India's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sanofi India's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sanofi India (BOM:500674) has a PB Ratio of 10.36 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi India and its competitors. This is 120% above median its historical median of 4.70. Over the past decade, Sanofi India's PB Ratio has ranged from 2.68 to 24.70. According to the industry distribution chart, Sanofi India ranks #856 out of 921 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Sanofi India's PB Ratio too high?
Sanofi India's current PB Ratio of 10.36 is 120% above median its 10-year median of 4.70. Over the past 10 years, this metric has ranged from a low of 2.68 to a high of 24.70. The Drug Manufacturers industry median PB Ratio is 1.90. Sanofi India's value of 10.36 is 445.3% above this industry median. Based on the distribution chart, Sanofi India ranks #856 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #856 out of 921 companies for PB Ratio. This places Sanofi India in the lower half of its industry. The industry median PB Ratio is 1.90. Sanofi India's value of 10.36 is 445.3% above this benchmark. Historically, Sanofi India's own PB Ratio has ranged from 2.68 to 24.70 over the past decade. While the company's 10-year median is 4.70 vs. the industry median of 1.90, Sanofi India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi India's current PB Ratio of 10.36 is 445.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanofi India and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi India's current PB Ratio is 10.36, which is 120% above median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,404.20, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current PB Ratio is 10.36, which is 120% above median its 10-year median of 4.70 and 445.3% above the Drug Manufacturers industry median of 1.90. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current PB Ratio is 10.36 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,404.20.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
PB Ratio: 10.36 (120% above median its 10-year median of 4.70)
GF Value™: ₹4,404.20 vs. price of ₹3,369.25 (23.5% below fair value)
Industry Position: 445.3% above the Drug Manufacturers median (#856 of 921)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
